Kosilov Kirill V, Kuzina Irina G, Kuznetsov Vladimir, Kosilova Ekaterina K
Department of Social Sciences, School of Humanities, Far Eastern Federal University, Vladivostok, Primorsky Region, Russian Federation.
Department of Social Science, Far Eastern Federal University, Vladivostok, Primorsky Region, Russian Federation.
Prostate Int. 2020 Jun;8(2):78-84. doi: 10.1016/j.prnil.2019.11.005. Epub 2020 Feb 25.
The aim of this research is to study the influence of simultaneous taking of tadalafil and solifenacin in standard and double dosage on the lower urinary tract symptoms (LUTS) and sexual dysfunction in men with benign prostatic hyperplasia after the course of dutasteride.
The research included 326 patients older than 50 years with benign prostatic hyperplasia coupled with LUTS and sexual dysfunction having undergone the course of treatment with dutasteride. After random division into three groups, patients from the Group A ( = 107) got tadalafil 5 mg/d as monotherapy, from the Group В ( = 107) got tadalafil 5 mg/d and solifenacin 10 mg/d, and from the Group С ( = 112) got tadalafil 5 mg/d and solifenacin 20 mg/d. The duration of treatment was 12 weeks. The rating of sexual function was made with the questionnaires International Index of Erectile Function and other.
The results of rating of sexual function with the questionnaires MSHQ-EjD and International Index of Erectile Function correlated among themselves. According to MSHQ-EjD, overall rating of the sexual function increased in each of the three groups (A: 67.9 (12.4)/91.5 (10.4), ≤ 0.05; B: 72.4 (14.5)/102.6 (16.9), ≤ 0.05; C: 76.6 (16.3)/109.6 (15.6), ≤ 0.05). The level of hyperactivity symptoms decreased in Groups В and С (В: urgency -2.9 (0.7)/1.1 (0.6), ≤ 0.05; nocturia 2.7 (1.0)/0.7 (0.5), ≤ 0.05; C: urgency -2.5 (0.5)/0.8 (0.6), ≤ 0.05; nocturia -2.8 (0.6)/1.0 (0.5), ≤ 0.05), and it did not change in the Group A.
The use of tadalafil as monotherapy significantly improves the sexual function but does not affect overactive bladder symptoms. The combination therapy of tadalafil and solifenacin leads to dramatic improvement of sexual function and reversibility of detrusor hyperactivity symptoms.
本研究旨在探讨在度他雄胺疗程结束后，标准剂量和双倍剂量的他达拉非与索利那新同时服用对良性前列腺增生男性下尿路症状（LUTS）和性功能障碍的影响。
该研究纳入了326例年龄超过50岁、患有良性前列腺增生并伴有LUTS和性功能障碍且已接受过度他雄胺治疗的患者。随机分为三组后，A组（n = 107）患者接受他达拉非5mg/d单药治疗，B组（n = 107）患者接受他达拉非5mg/d和索利那新10mg/d治疗，C组（n = 112）患者接受他达拉非5mg/d和索利那新20mg/d治疗。治疗持续时间为12周。采用国际勃起功能指数等问卷对性功能进行评分。
使用MSHQ-EjD问卷和国际勃起功能指数对性功能进行评分的结果相互关联。根据MSHQ-EjD，三组患者的性功能总体评分均有所提高（A组：67.9(12.4)/91.5(10.4)，P≤0.05；B组：72.4(14.5)/102.6(16.9)，P≤0.05；C组：76.6(16.3)/109.6(15.6)，P≤0.05）。B组和C组的膀胱过度活动症状水平降低（B组：尿急-2.9(0.7)/1.1(0.6)，P≤0.05；夜尿2.7(1.0)/0.7(0.5)，P≤0.05；C组：尿急-2.5(0.5)/0.8(0.6)，P≤0.05；夜尿-2.8(0.6)/1.0(0.5)，P≤0.05），而A组未发生变化。
他达拉非单药治疗可显著改善性功能，但不影响膀胱过度活动症状。他达拉非与索利那新联合治疗可显著改善性功能，并使逼尿肌过度活动症状可逆。
